Venetoclax and Azacitidine Before Stem Cell Transplant in Higher-Risk Myelodysplastic Syndromes
Tests venetoclax with azacitidine before stem cell transplant in adults with higher-risk myelodysplastic syndromes.
Plain-language title generated from the registry record
Registry title: Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes
Key facts
- Where
- Changchun, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed high-risk myelodysplastic syndrome who are planned to have a stem cell transplant from a donor.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Newly diagnosed myelodysplastic syndrome (MDS) confirmed by bone marrow tests, with bone marrow blasts of at least 10% and an IPSS-R score above 4.5
- Earlier treatment
- Must be scheduled for an allogeneic hematopoietic stem cell transplant (a transplant of blood-forming cells from a donor)
Main reasons for not taking part
- Disease outside the bone marrow
- Severe heart disease
- Active tuberculosis or HIV infection
- Another cancer, unless it was treated and is gone
- Pregnancy or breastfeeding
Read by machine on 12 November 2026.
Where in China
- The First Hospital of Jilin UniversityChangchun, ChinaContact: Yehui TanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Yehui Tan
- Trial code
- NCT07047183
- Record updated
- 8 August 2025
- Original description
A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Azacitidine Followed by Bridging Transplantation in Patients with High-Risk Myelodysplastic Neoplasms with Increased Blasts 2 (MDS-IB2)Read full original descriptionShow less
A Single-Arm, Prospective Clinical Study of Venetoclax Combined With Azacitidine Followed by Bridging Transplantation in Patients With High-Risk Myelodysplastic Neoplasms With Increased Blasts 2 (MDS-IB2)
A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Azacitidine Followed by Bridging Transplantation in Patients with High-Risk Myelodysplastic Neoplasms with Increased Blasts 2 (MDS-IB2)
Inclusion: Newly diagnosed MDS confirmed by morphological and immunophenotypic analysis of bone marrow；; Age ≥18 years, any gender；; Bone marrow blasts ≥10%；; IPSS-R score >4.5；; ECOG performance status 0-2；; Scheduled for allogeneic hematopoietic stem cell transplantation (allo-HSCT)；; Adequate major organ function：; Cardiac: LVEF ≥50%; Hepatic: Bilirubin ≤1.5×ULN; AST/ALT ≤2.5×ULN; Renal: Creatinine clearance ≥60 mL/min；; Written informed consent provided by the patient or legally authorized representative.
Exclusion: Concurrent malignant tumors of other organs, which can be enrolled if previously cured; Concomitant hematologic disorders; Extramedullary disease involvement；; Hypersensitivity to any study drugs；; Severe cardiac disease, including congestive heart failure, myocardial infarction, and cardiac insufficiency; Active tuberculosis or HIV infection; Clinically significant hepatic/renal dysfunction exceeding inclusion thresholds；; Pregnancy or lactation; Inability to comply with protocol requirements; Concurrently participating in other clinical studies.